# A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

> **NCT00022672** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 208 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** trastuzumab (Herceptin®)
- **DRUG:** anastrazole (Arimidex®)

## Key facts

- **NCT ID:** NCT00022672
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2013-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022672, "A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00022672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*